nach oben

International Journal of Clinical Oncology

Erschienen in:

01.12.2015 | Original Article

Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status

verfasst von: Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status.

Patients and methods

Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status.

Results

Sixty-eight patients were prospectively treated with meloxicam. MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3–4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment.

Conclusion

MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status.

Posner MC, Shiu MH, Newsome JL et al (1989) The desmoid tumor. Arch Surg 124(2):191–196CrossRefPubMed

Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17(1):158–167PubMed

Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21(7):1390–1397CrossRefPubMed

Huang K, Fu H, Shi YQ et al (2009) Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 100(7):563–569CrossRefPubMed

Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25(13):1785–1791CrossRefPubMed

Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86(10):2045–2052CrossRefPubMed

Nuyttens JJ, Rust PF, Thomas CR Jr et al (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88(7):1517–1523CrossRefPubMed

Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29(26):3553–3558CrossRefPubMed

Shido Y, Nishida Y, Nakashima H et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Traum Surg 129(7):929–933CrossRef

10.

Colombo C, Miceli R, Lazar AJ et al (2013) CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119(20):3696–3702CrossRefPubMed

11.

Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173(5):1518–1527PubMedCentralCrossRefPubMed

12.

van Broekhoven DL, Verhoef C, Grunhagen DJ et al (2015) Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 22(5):1464–1470CrossRefPubMed

13.

Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96(8):631–638CrossRefPubMed

14.

Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25(3):578–583PubMedCentralCrossRefPubMed

15.

Nishida Y, Tsukushi S, Shido Y et al (2010) Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 28(6):e107–e109CrossRefPubMed

16.

Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 60(7):1108–1112PubMedCentralCrossRefPubMed

17.

de Camargo VP, Keohan ML, D’Adamo DR et al (2010) Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 116(9):2258–2265PubMedCentralPubMed

18.

Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24(1):102–105CrossRefPubMed

19.

Poon R, Smits R, Li C et al (2001) Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20(4):451–460CrossRefPubMed

20.

Hamada S, Urakawa H, Kozawa E et al (2014) Nuclear expression of beta-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol 35(5):4561–4566CrossRefPubMed

21.

Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92(5):1259–1264CrossRefPubMed

22.

Lackner H, Urban C, Kerbl R (1997) Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 80(2):334–340CrossRefPubMed

23.

Hamada S, Futamura N, Ikuta K et al (2014) CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One 9(5):e96391PubMedCentralCrossRefPubMed

24.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed

25.

Skapek SX, Ferguson WS, Granowetter L et al (2007) Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 25(5):501–506CrossRefPubMed

26.

Meazza C, Bisogno G, Gronchi A et al (2010) Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 116(1):233–240PubMed

27.

Garbay D, Le Cesne A, Penel N et al (2012) Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 23(1):182–186CrossRefPubMed

28.

Domont J, Salas S, Lacroix L et al (2010) High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 102(6):1032–1036PubMedCentralCrossRefPubMed

29.

Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16(19):4884–4891CrossRefPubMed

30.

Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24(7):1195–1203CrossRefPubMed

31.

Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22(2):452–457CrossRefPubMed

32.

Gounder MM, Lefkowitz RA, Keohan ML et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17(12):4082–4090PubMedCentralCrossRefPubMed

33.

Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Investig New Drugs 32(2):369–376CrossRef

34.

Bonvalot S, Eldweny H, Haddad V et al (2008) Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 34(4):462–468CrossRefPubMed

Titel: Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status
verfasst von: Yoshihiro Nishida
Satoshi Tsukushi
Hiroshi Urakawa
Shunsuke Hamada
Eiji Kozawa
Kunihiro Ikuta
Yuichi Ando
Naoki Ishiguro
Publikationsdatum: 01.12.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0829-0

Springer Medizin

Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status